⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069786 | 1.00 | — | — | |
| SCHEMBL15927761 | 1.00 | — | — | |
| SCHEMBL1037843 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL22540086 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL14620877 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL24912524 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL14772 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL6426932 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL165540 | 0.94 | ALDH1A1 (0.47) | — | |
| SCHEMBL5114077 | 0.94 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | claimed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119365454-A | Discovery of covalent EGFR inhibitors through cysteine 775 | 丹娜-法伯癌症研究院 | 2025-01-24 | — | — | CN | claimed |
| CN-117377675-A | Bruton's tyrosine kinase degradation agent containing parallel ring or spiro ring | 正大天晴药业集团股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| EP-4298095-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | Sperogenix Therapeutics Limited (HK) | 2024-01-03 | — | — | EP | claimed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | claimed |
| WO-2022162606-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LIMITED (CN) | 2022-08-04 | — | — | WO | claimed |
| EP-0273514-A1 | Novel bicyclic diphosphonate compounds and pharmaceutical compositions | Norwich Eaton Pharmaceuticals, Inc. (US) | 1988-07-06 | — | — | EP | claimed |
| US-4713459-A | TRANSFERRING OXYGEN FOR HEMORRHAGE VICTIMS, PRESERVING ORGANS FOR SURGERY | THE GREEN CROSS CORPORATION (JP) | 1987-12-15 | — | — | US | claimed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| CN-116249701-B | Substituted di (pyridin-2-yl) amine derivatives, compositions and pharmaceutical uses thereof | 上海海雁医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119768404-A | Heteroaryl substituted pyridopyrrolidone derivatives, pharmaceutical compositions and uses thereof | 上海海雁医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-1996018630-A1 | BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995013279-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-18 | — | — | WO | disclosed |
| EP-0273514-A1 | Novel bicyclic diphosphonate compounds and pharmaceutical compositions | Norwich Eaton Pharmaceuticals, Inc. (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4337341-A | 4a-Aryl-octahydro-1H-2-pyrindines | ELI LILLY AND COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0002937-A1 | Novel pyrindines and their preparation, formulations and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |